2025国家医保谈判启动，新增商保创新药协商，预计为期4~5天

Core Insights - The 2025 National Medical Insurance Negotiation has commenced, expected to last 4-5 days, focusing on both basic medical insurance and commercial health insurance innovative drug pricing [1][2] - This year's negotiation marks the 8th adjustment since the establishment of the National Medical Insurance Bureau and introduces a new commercial health insurance innovative drug directory [2][3] Group 1: Negotiation Details - The negotiation will begin with drugs that have relatively transparent pricing, such as antiviral and chronic disease medications, while more challenging drugs like cancer treatments will be discussed later [3] - Key innovative drugs, including TROP2 ADC and several CAR-T products, are anticipated to participate in this year's negotiations [2][3] Group 2: Directory Adjustments - A total of 535 drug names have passed the formal review for the basic drug directory, with 311 being new entries and 224 existing ones [2] - For the commercial health insurance innovative drug directory, 121 drug names have passed the formal review, with 79 applying for both directories [2][3] Group 3: Policy Framework - The dynamic adjustment mechanism for the national medical insurance directory has evolved into a scientific and fair process over the years [3] - The commercial health insurance innovative drug directory focuses on high-innovation, clinically valuable drugs that cannot be included in the basic directory due to their cost [3]